🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: BTCT4465A (Mosunetuzumab) SC

Found 9 matching trials

A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

PHASE1

This study will evaluate the safety, tolerability, pharmacokinetics, pharma...

Status

Active Not Recruiting

Location

University of Alabama at Birmingham School of Medicine

Start Date

2018-09-25

Trial ID

NCT03671018

Treatments Being Tested

Mosunetuzumab (IV)Mosunetuzumab (SC)Polatuzumab vedotin Tocilizumab Rituximab

Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

PHASE2

This phase II trial tests how well pirtobrutinib and mosunetuzumab work in ...

Status

Recruiting

Location

Fred Hutch/University of Washington Cancer Consortium

Start Date

2025-11-17

Trial ID

NCT06948786

Treatments Being Tested

Pirtobrutinib Mosunetuzumab Biospecimen Collection Biopsy Procedure Computed Tomography Positron Emission Tomography Bone Marrow Aspiration Bone Marrow Biopsy Questionnaire Administration

Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment

PHASE2

This phase II trial compares the effect of mosunetuzumab alone to mosunetuz...

Status

Not Yet Recruiting

Location

Multiple Locations

Start Date

2026-10-03

Trial ID

NCT07638722

Treatments Being Tested

Biospecimen Collection Bone Marrow Biopsy Computed Tomography Mosunetuzumab Polatuzumab Vedotin Positron Emission Tomography Survey Administration Zanubrutinib

A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

PHASE1

This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) admi...

Status

Completed

Location

University of California San Diego Moores Cancer Center

Start Date

2015-09-15

Trial ID

NCT02500407

Treatments Being Tested

BTCT4465A (Mosunetuzumab) IV Atezolizumab BTCT4465A (Mosunetuzumab) SC

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

PHASE3

This phase III trial compares the effectiveness of rituximab to mosunetuzum...

Status

Recruiting

Location

University of Alabama at Birmingham Cancer Center

Start Date

2024-10-23

Trial ID

NCT06337318

Treatments Being Tested

Biospecimen Collection Computed Tomography Mosunetuzumab Positron Emission Tomography Rituximab Rituximab and Hyaluronidase Human

Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

PHASE1

This study will evaluate the safety, pharmacokinetics, and preliminary effi...

Status

Completed

Location

University of Alabama at Birmingham School of Medicine

Start Date

2019-05-23

Trial ID

NCT03677154

Treatments Being Tested

Mosunetuzumab Intravenous (IV)Mosunetuzumab Subcutaneous (SC)Polatuzumab Vedotin Tocilizumab

Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

PHASE2

This phase II trial tests the effects of mosunetuzumab with or without pola...

Status

Completed

Location

Fred Hutch/University of Washington Cancer Consortium

Start Date

2022-03-23

Trial ID

NCT05169658

Treatments Being Tested

Mosunetuzumab Obinutuzumab Polatuzumab Vedotin FDG-Positron Emission Tomography Computed Tomography Positron Emission Tomography Bone Marrow Biopsy Bone Marrow Aspiration Biospecimen Collection

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial

PHASE2

This phase II trial compares mosunetuzumab to the usual treatment (rituxima...

Status

Recruiting

Location

City of Hope Comprehensive Cancer Center

Start Date

2024-01-23

Trial ID

NCT05886036

Treatments Being Tested

Biopsy Procedure Biospecimen Collection Bone Marrow Biopsy Computed Tomography Fludeoxyglucose F-18 Mosunetuzumab Positron Emission Tomography Rituximab Rituximab and Hyaluronidase Human

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

PHASE2

This phase II trial tests how well mosunetuzumab and polatuzumab vedotin wo...

Status

Recruiting

Location

City of Hope Medical Center

Start Date

2024-09-09

Trial ID

NCT06453044

Treatments Being Tested

Biospecimen Collection Computed Tomography Magnetic Resonance Imaging Mosunetuzumab Polatuzumab Vedotin Positron Emission Tomography Questionnaire Administration

Previous Next